At concentrations of 0.25% and 0.5% AI, dose-dependent improvements were observed in the major parameters of hypertriglyceridemia, such as plasma TG, FFA, ApoB, and LPL levels. This evidence concerns the gene APOB and hypertriglyceridemia.